Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Mallinckrodt
Medtronic
Johnson and Johnson
Cipla
AstraZeneca

Generated: September 17, 2019

DrugPatentWatch Database Preview

Patent: 9,802,984

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,802,984
Title:Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases
Abstract: Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, an isolated peptide comprising the amino acid sequence LRRFSTAPFAFIDINDVINF, which exhibits anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumorigenic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models is disclosed. The isolate peptide also exhibits anti-lymphangiogenic and directly anti-tumorigenic properties.
Inventor(s): Popel; Aleksander S. (Lutherville-Timonium, MD), Pandey; Niranjan B. (White Marsh, MD), Lee; Esak (Windsor Mill, MD), Green; Jordan J. (Nottingham, MD), Shmueli; Ron B. (Baltimore, MD)
Assignee: THE JOHNS HOPKINS UNIVERSITY (Baltimore, MD)
Application Number:14/896,521
Patent Claims:see list of patent claims

Details for Patent 9,802,984

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26 ➤ Sign Up THE JOHNS HOPKINS UNIVERSITY (Baltimore, MD) 2033-06-07 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26 ➤ Sign Up THE JOHNS HOPKINS UNIVERSITY (Baltimore, MD) 2033-06-07 RX search
Genentech LUCENTIS ranibizumab INJECTABLE; INJECTION 125156 001 2006-06-30 ➤ Sign Up THE JOHNS HOPKINS UNIVERSITY (Baltimore, MD) 2033-06-07 RX search
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18 ➤ Sign Up THE JOHNS HOPKINS UNIVERSITY (Baltimore, MD) 2033-06-07 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Healthtrust
Cantor Fitzgerald
Citi
Teva
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.